AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33870448 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 33870448 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 0
Study 33493011 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Dose Aspirin (LDA) for 5 of 7 days per week
Number of subjects: 1227
Study 33493011 — intervention group
Group type: COMPARATOR
Intervention: Postconception initiation of LDA therapy
Number of subjects: 1227
Study 34320428 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 J.cm−2 LED, 600 μmol.L−1 curcumin
Number of subjects: 0
Study 34320428 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 μmol.L−1 curcumin plus 17% EDTA
Number of subjects: 0
Study 34320428 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 μmol.L−1 curcumin plus 18% HEBP
Number of subjects: 0
Study 34320428 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 μmol.L−1 curcumin plus 75 J.cm−2 LED
Number of subjects: 0
Study 34320428 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 μmol.L−1 curcumin plus 17% EDTA and 75 J.cm−2 LED
Number of subjects: 0
Study 34320428 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 μmol.L−1 curcumin plus 18% HEBP and 75 J.cm−2 LED
Number of subjects: 0
Study 34320428 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 34529859 — intervention group
Group type: EXPERIMENTAL
Intervention: LED treatment (590, 630, and 850 nm with two tested irradiances each)
Number of subjects: 10
Study 34529859 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 10
Study 32176657 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually Tailored Internet-Based Cognitive Behavioral Therapy (ICBT) combined with standard medical treatment
Number of subjects: 77
Study 32176657 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment plus being on waitlist to ICBT (CONTROL)
Number of subjects: 77
Study 32176657 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually Tailored Internet-Based Cognitive Behavioral Therapy (ICBT)
Number of subjects: 77
Study 35412032 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide orodispersible tablet (BOT) 1 mg BID for 6 weeks
Number of subjects: 181
Study 33638144 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini PCNL
Number of subjects: 50
Study 33638144 — intervention group
Group type: COMPARATOR
Intervention: RIRS
Number of subjects: 50
Study 33638144 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 50
Study 34225765 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (VPA) for 4 months
Number of subjects: 110
Study 34225765 — intervention group
Group type: COMPARATOR
Intervention: Observation only for 4 months
Number of subjects: 110
Study 33933921 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and notifying the primary care provider (PCP)
Number of subjects: 1500
Study 33933921 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening, notifying the PCP, and providing enhanced depression treatment
Number of subjects: 1500
Study 33933921 — intervention group
Group type: COMPARATOR
Intervention: No screening
Number of subjects: 1500
Study 33933921 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen and Notify vs No Screen
Number of subjects: 1500
Study 33933921 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 1500
Study 35339669 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind peppermint oil (DBM)
Number of subjects: 173
Study 35339669 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Number of subjects: 173
Study 35339669 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind placebo (DBP)
Number of subjects: 173
Study 33589408 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip plus maximally tolerated guideline‐directed medical therapy (GDMT)
Number of subjects: 575
Study 33589408 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip
Number of subjects: 575
Study 33589408 — intervention group
Group type: COMPARATOR
Intervention: GDMT alone
Number of subjects: 575
Study 32820838 — intervention group
Group type: EXPERIMENTAL
Intervention: EB-HF (energy balance with high fat)
Number of subjects: 9
Study 32820838 — intervention group
Group type: COMPARATOR
Intervention: ED-LF (energy deficit with low fat)
Number of subjects: 9
Study 35354299 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigorous preclinical assessment with treatment masking, randomization, and blinded assessment.
Number of subjects: 913
Study 35354299 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized procedural implementation across laboratories.
Number of subjects: 913
Study 35354299 — intervention group
Group type: COMPARATOR
Intervention: Randomized, placebo-controlled, blinded trial design.
Number of subjects: 913
Study 32428843 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise twice a week (2x/w)
Number of subjects: 60
Study 32428843 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise three times a week (3x/w)
Number of subjects: 60
Study 32428843 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (ACC)
Number of subjects: 60
Study 34896280 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based music therapy intervention (4 sessions over 12 weeks)
Number of subjects: 37
Study 32648081 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement (AVR)
Number of subjects: 0
Study 32648081 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 0
Study 32648081 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study 36441220 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited tourniquet (LT)
Number of subjects: 100
Study 36441220 — intervention group
Group type: COMPARATOR
Intervention: Conventional tourniquet (CT)
Number of subjects: 100
Study 33826537 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (DES)
Number of subjects: 53
Study 33826537 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloons (DCB)
Number of subjects: 53
Study 35636734 — intervention group
Group type: EXPERIMENTAL
Intervention: Acting with Mindfulness for Pain (AMP)
Number of subjects: 86
Study 35636734 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 86
Study 34090515 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric integrative manual therapy (PIMT) plus caregiver education program
Number of subjects: 34
Study 34090515 — intervention group
Group type: COMPARATOR
Intervention: Control group (caregiver education program only)
Number of subjects: 34
Study 34650004 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Number of subjects: 142
Study 34650004 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary rehabilitation
Number of subjects: 142
Study 33907210 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) applied with a GaAlAs laser (wavelength=810 nm) at pre-determined points in the masseter muscle (6 J/cm2, 3 regions, 60 s) or TMJ region (6 J/cm2, 5 points, 30 s) for 7 consecutive days.
Number of subjects: 175
Study 33907210 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 7 consecutive days.
Number of subjects: 175
Study 33907210 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Number of subjects: 175
Study 33907210 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 175
Study 33984725 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative dose-dense adjuvant chemotherapy with bevacizumab maintenance after neoadjuvant chemotherapy
Number of subjects: 22
Study 32340471 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Number of subjects: 0
Study 32340471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36073608 — intervention group
Group type: EXPERIMENTAL
Intervention: Sini powder (SNP)
Number of subjects: 36
Study 34626843 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrabrief pulse width (UB: 0.3 ms) ECT
Number of subjects: 9
Study 34626843 — intervention group
Group type: COMPARATOR
Intervention: Brief pulse width (BP: 1.0 ms) ECT with frontoparietal (FP) placement
Number of subjects: 9
Study 34626843 — intervention group
Group type: COMPARATOR
Intervention: Higher E-fields in regions-of-interest with TP ECT
Number of subjects: 9
Study 32562573 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg daily low-dose aspirin
Number of subjects: 13547
Study 32562573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13547
Study 34028506 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery
Number of subjects: 0
Study 34028506 — intervention group
Group type: COMPARATOR
Intervention: Community Weight Management Intervention
Number of subjects: 0
Study 33225834 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D CMIE
Number of subjects: 98
Study 33225834 — intervention group
Group type: COMPARATOR
Intervention: 2D CMIE
Number of subjects: 98
Study 33686753 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib + endocrine therapy (ET) in MONARCH 2
Number of subjects: 356
Study 33686753 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib + endocrine therapy (ET) in MONARCH 3
Number of subjects: 356
Study 33686753 — intervention group
Group type: COMPARATOR
Intervention: Adverse events in MONARCH 2
Number of subjects: 356
Study 33686753 — intervention group
Group type: COMPARATOR
Intervention: Adverse events in MONARCH 3
Number of subjects: 356
Study 33378517 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol-containing toothbrushes
Number of subjects: 44
Study 33378517 — intervention group
Group type: COMPARATOR
Intervention: Xylitol-free toothbrushes (Control)
Number of subjects: 44
Study 33896276 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir + ritonavir-boosted darunavir (2DR)
Number of subjects: 263
Study 33896276 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care therapy with two nucleoside reverse transcriptase inhibitors + DRV/r (3DR)
Number of subjects: 263
Study 33418367 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-psycho-social treatment programme (6-7 months)
Number of subjects: 321
Study 32068890 — intervention group
Group type: EXPERIMENTAL
Intervention: CNN-based classifier
Number of subjects: 24667
Study 32068890 — intervention group
Group type: COMPARATOR
Intervention: Clinical visual assessments (CVAs) by 12 otolaryngologists
Number of subjects: 24667
Study 34985366 — intervention group
Group type: EXPERIMENTAL
Intervention: rPMS (20Hz and 2400 pulses to triceps brachii and extensor digitorum muscles daily for two weeks in addition to conventional physiotherapy)
Number of subjects: 44
Study 33513313 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus ipilimumab
Number of subjects: 568
Study 33513313 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab plus placebo
Number of subjects: 568
Study 32412970 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable resistance training (uRT)
Number of subjects: 55
Study 32412970 — intervention group
Group type: COMPARATOR
Intervention: Stable resistance training (sRT)
Number of subjects: 55
Study 33497833 — intervention group
Group type: EXPERIMENTAL
Intervention: mPCST-Community
Number of subjects: 180
Study 33497833 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 180
Study 34503850 — intervention group
Group type: EXPERIMENTAL
Intervention: Open total gastrectomy (OTG)
Number of subjects: 96
Study 34503850 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive total gastrectomy (MITG)
Number of subjects: 96
Study 33285037 — intervention group
Group type: EXPERIMENTAL
Intervention: Viltolarsen 40 mg/kg/week
Number of subjects: 16
Study 33285037 — intervention group
Group type: EXPERIMENTAL
Intervention: Viltolarsen 80 mg/kg/week
Number of subjects: 16
Study 34394103 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention
Number of subjects: 14
Study 34394103 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (non-exercised group)
Number of subjects: 14
Study 33077839 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACT) after radical nephroureterectomy (RNU)
Number of subjects: 176
Study 33077839 — intervention group
Group type: EXPERIMENTAL
Intervention: RNU + ACT
Number of subjects: 176
Study 33077839 — intervention group
Group type: EXPERIMENTAL
Intervention: RNU + ACT in T3/4 cohort
Number of subjects: 176
Study 33077839 — intervention group
Group type: COMPARATOR
Intervention: RNU
Number of subjects: 176
Study 33655812 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-linear periodized resistance training (NLP)
Number of subjects: 28
Study 33655812 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear periodized resistance training (LP)
Number of subjects: 28
Study 33655812 — intervention group
Group type: COMPARATOR
Intervention: Both LP and NLP
Number of subjects: 28
Study 33235349 — intervention group
Group type: EXPERIMENTAL
Intervention: Teller Acuity Cards II
Number of subjects: 0
Study 32212282 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-world evidence (RWE) studies
Number of subjects: 7267
Study 32212282 — intervention group
Group type: EXPERIMENTAL
Intervention: RWE studies categorized as medical records
Number of subjects: 7267
Study 32212282 — intervention group
Group type: EXPERIMENTAL
Intervention: RWE for gastroenterological diseases
Number of subjects: 7267
Study 32212282 — intervention group
Group type: EXPERIMENTAL
Intervention: RWE for respiratory diseases
Number of subjects: 7267
Study 32212282 — intervention group
Group type: EXPERIMENTAL
Intervention: RWE for older drugs
Number of subjects: 7267
Study 35980080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (IMN)
Number of subjects: 240
Study 35980080 — intervention group
Group type: COMPARATOR
Intervention: External fixation (EF)
Number of subjects: 240
Study 33543484 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis (n = 91)
Number of subjects: 133
Study 33543484 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 42)
Number of subjects: 133
Study 33402248 — intervention group
Group type: EXPERIMENTAL
Intervention: Health warning labels (HWLs) placed on waterpipe (stem, water bowl, hose)
Number of subjects: 74
Study 33402248 — intervention group
Group type: EXPERIMENTAL
Intervention: Health warning labels (HWLs)
Number of subjects: 74
Study 35018094 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐AbA 300 mg
Number of subjects: 76
Study 35018094 — intervention group
Group type: COMPARATOR
Intervention: R‐AbA 1000 mg
Number of subjects: 76
Study 35018094 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐AbA on a high-fat diet
Number of subjects: 76
Study 35018094 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐AbA and SNAC
Number of subjects: 76
Study 35018094 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAC
Number of subjects: 76
Study 35018094 — intervention group
Group type: EXPERIMENTAL
Intervention: Food effect on N‐AbA
Number of subjects: 76
Study 33768581 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Message
Number of subjects: 160
Study 33768581 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition Message
Number of subjects: 160
Study 33768581 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 160
Study 32464936 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (DA)
Number of subjects: 82
Study 32464936 — intervention group
Group type: COMPARATOR
Intervention: Control (no dopamine)
Number of subjects: 82
Study 36256630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean delivery (CD)
Number of subjects: 737904
Study 35001668 — intervention group
Group type: EXPERIMENTAL
Intervention: Thai traditional massage for 4 weeks
Number of subjects: 45
Study 35001668 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg daily
Number of subjects: 45
Study 34736388 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (n=40)
Number of subjects: 89
Study 34736388 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (n=49)
Number of subjects: 89
Study 33985532 — intervention group
Group type: EXPERIMENTAL
Intervention: PLAN-A intervention (peer-led physical activity program)
Number of subjects: 1558
Study 33985532 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 1558
Study 35689208 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam tosilate (RT) 0.15 mg/kg with supplemental doses of 0.05 mg/kg as needed
Number of subjects: 82
Study 35689208 — intervention group
Group type: COMPARATOR
Intervention: Propofol 1.5 mg/kg with supplemental doses of 0.5 mg/kg
Number of subjects: 82
Study 35689208 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam tosilate (RT)
Number of subjects: 82
Study 35689208 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 82
Study 34544853 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 extra hours of self-selected, task-specific motor therapy starting at 2 to 3 months after stroke (subacute group)
Number of subjects: 0
Study 34544853 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 extra hours of self-selected, task-specific motor therapy starting at ?30 days after stroke (acute group)
Number of subjects: 0
Study 34544853 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 extra hours of self-selected, task-specific motor therapy starting at ?6 months after stroke (chronic group)
Number of subjects: 0
Study 35157791 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg 3 times daily
Number of subjects: 44
Study 35157791 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg 3 times daily
Number of subjects: 44
Study 35157791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 35157791 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 44
Study 34969405 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction associated with passive mobilization (BFRp)
Number of subjects: 39
Study 34969405 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction associated with electrical stimulation (BFRpE)
Number of subjects: 39
Study 34969405 — intervention group
Group type: COMPARATOR
Intervention: Passive mobilization (PM)
Number of subjects: 39
Study 36367009 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiome supporting (MS) products
Number of subjects: 14
Study 36367009 — intervention group
Group type: COMPARATOR
Intervention: Benchmark (BM) products
Number of subjects: 14
Study 32145405 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep condition
Number of subjects: 0
Study 32145405 — intervention group
Group type: COMPARATOR
Intervention: Wake condition
Number of subjects: 0
Study 32145405 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling parameter considering accuracy and response time
Number of subjects: 0
Study 34730989 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy
Number of subjects: 387
Study 34730989 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 387
Study 34161979 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ICU aftercare practices (dietary restrictions, bed rest orders, bladder catheter, advance directive documentation, dysphagia, functional decline, delirium)
Number of subjects: 151
Study 34161979 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Charlson Comorbidity Index
Number of subjects: 151
Study 34161979 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine use on medical units
Number of subjects: 151
Study 34161979 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation in the ICU
Number of subjects: 151
Study 34161979 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder catheters
Number of subjects: 151
Study 32056158 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative duration of intraoperative hypotension (SAP < 80% pre-induction value)
Number of subjects: 52
Study 32056158 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Comprehensive Complication Index
Number of subjects: 52
Study 32056158 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest absolute SAP
Number of subjects: 52
Study 32056158 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest absolute MAP
Number of subjects: 52
Study 35135684 — intervention group
Group type: EXPERIMENTAL
Intervention: Early artificial rupture of membranes
Number of subjects: 160
Study 35135684 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 160
Study 33798763 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 1, 2, and 3 mA for 15, 20, and 30 min
Number of subjects: 32
Study 33798763 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 3 mA for 20 min
Number of subjects: 32
Study 33798763 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 3 mA for 30 min
Number of subjects: 32
Study 33798763 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 32
Study 32055820 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory diet
Number of subjects: 50
Study 32055820 — intervention group
Group type: COMPARATOR
Intervention: Control diet (similar to general dietary intake in Sweden)
Number of subjects: 50
Study 35108059 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg intravenously; administered once every 2 weeks for 12 months)
Number of subjects: 713
Study 35108059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 713
Study 34802961 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous mitral valve repair (pMVR)
Number of subjects: 144
Study 35289303 — intervention group
Group type: EXPERIMENTAL
Intervention: No stenting
Number of subjects: 603
Study 35289303 — intervention group
Group type: COMPARATOR
Intervention: Immediate stenting
Number of subjects: 603
Study 34653557 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT+RT (high-intensity interval training combined with resistance training), n=12
Number of subjects: 40
Study 34653557 — intervention group
Group type: EXPERIMENTAL
Intervention: MICT+RT (moderate-intensity continuous training combined with resistance training), n=13
Number of subjects: 40
Study 34653557 — intervention group
Group type: EXPERIMENTAL
Intervention: RT (resistance training alone), n=15
Number of subjects: 40